Tenecteplase plus a second drug for stroke recovery
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether giving a second drug (urinary kallidinogenase) after the clot-busting drug tenecteplase can help people with moderate to severe ischemic strokes recover better. It is for patients who started treatment within 4.5 hours of symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had a stroke caused by a blocked blood vessel, confirmed by brain imaging
- You started treatment within 4.5 hours of the first symptoms
- You received a clot-busting drug called tenecteplase (0.25 mg/kg)
- This is your first stroke, or a past stroke that left no lasting disability
- You are not planning to have surgery to remove the clot
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a second dose of a clot-busting drug (tenecteplase) helps people who had a stroke and didn't improve much after the first dose. You must receive the second dose within 4.5 hours of your stroke symptoms starting.
This trial tests if giving a second dose of the clot-busting drug tenecteplase can help people whose stroke symptoms don't improve after the first dose, when a large or medium artery in the brain is still blocked. It may be an option for patients who cannot have a mechanical clot removal procedure.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery after a successful mechanical clot removal can improve recovery for people with a certain type of stroke. The goal is to see if it safely helps clear any remaining tiny clots and reduces disability.
This trial tests a medicine called tenecteplase (a clot-buster) for people who have a moderate or severe stroke caused by a clot and can be treated 4.5 to 6 hours after symptoms start. It aims to see if this medicine can help improve recovery.
This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.
This study tests whether giving a clot-busting drug called tenecteplase directly into the brain's blood vessels can help complete the removal of a clot after a first attempt at mechanical extraction was only partially successful.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.